Skip to content
Insider tapeFilings through Fri, Oct 16
Watchlist

Sanjay Chanda

Chief Development Officer at AN2 Therapeutics, Inc. (ANTX)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $9K

Reported trades

Filed Stock Type Shares Price Value Since
Jan 7SEC ANTXAN2 Therapeutics, Inc. Sell 3,29581,779 held (−4%) $1.00 $3K +238.0%
Jan 7SEC ANTXAN2 Therapeutics, Inc. Sell 5,95675,823 held (−7%) $1.01 $6K +234.7%